AMBELVIST (Gadoquatrane) Patent Expiration, LOE Window & CMS Spending

AMBELVIST (Gadoquatrane) by Bayer: FDA Orange Book core substance LOE 2040-05-19, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayN219627 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-05-19
Last Listed Patent or Exclusivity Date2040-05-19
Orange Book Patents (*PED Extensions)36 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.